Skip to main content

Table 4 Predictors of reduced total, cortical, and trabecular bone mineral density in patients with nonradiographic axial spondyloarthritis

From: Cortical bone loss is an early feature of nonradiographic axial spondyloarthritis

 

Total BMD

Ct. BMD

Trab. BMD

β

T

p

β

T

p

β

T

p

Model 1

 Age

0.006

0.068

0.946

−0.038

−0.449

0.654

−0.073

− 0.952

0.342

 Sex (male vs. female)

− 0.143

−1.730

0.086

0.285

3.523

0.001

−0.466

−6.324

<  0.001

 BMI

0.079

0.915

0.362

−0.004

− 0.042

0.966

0.083

1.080

0.282

 Smoking (yes/no)

0.118

1.415

0.159

−0.041

− 0.505

0.615

0.103

1.378

0.171

 Intercept

–

11.570

<  0.001

–

29.784

<  0.001

–

12.765

<  0.001

 R2 adjusted

–

0.016

–

–

0.059

–

–

0.219

–

Model 2

 Age

−0.109

−0.913

0.364

−0.094

− 0.858

0.393

− 0.151

−1.498

0.138

 Sex

−0.095

−0.847

0.399

0.300

2.937

0.004

−0.420

−4.448

<  0.001

 BMI

0.115

1.036

0.303

0.017

0.164

0.870

0.159

1.689

0.095

 Remission

−0.017

−0.150

0.881

0.015

0.147

0.883

0.048

0.512

0.610

 Disease duration

0.157

1.241

0.218

−0.169

−1.460

0.148

0.280

2.625

0.010

 Anti-TNF

−0.094

−0.776

0.440

−0.131

−1.176

0.243

−0.160

−1.557

0.123

 GC (yes/no)

−0.132

−1.131

0.261

0.109

1.023

0.309

−0.205

−2.078

0.041

 HLA-B27 positivity

−0.027

−0.254

0.800

0.002

0.020

0.984

0.027

0.304

0.762

 Peripheral arthritis

0.011

0.095

0.924

−0.041

−0.404

0.687

−0.093

−0.987

0.327

 Intercept

–

8.522

<  0.001

–

23.225

<  0.001

–

9.761

<  0.001

 R2 adjusted

–

−0.038

–

–

0.130

–

–

0.258

–

  1. Abbreviations: BMD Bone mineral density, Ct. BMD Cortical bone mineral density, Trab. BMD Trabecular bone mineral density, axSpA axial spondyloarthritis, BMI Body mass index, Anti-TNF Current treatment with anti-tumor necrosis factor α inhibitor, GC History of glucocorticoid treatment with ≥ 5 mg prednisolone equivalent daily for > 3 mo
  2. Remission status according to Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP, inactive disease ASDAS-CRP < 1.3)
  3. Bold indicates significant differences (p < 0.05)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us